NEW YORK, Oct. 10 - Structural GenomiX has hired Mike Grey as chief business officer and has made him a member of the company’s board of directors, SGX said on Tuesday.
According to the company, Grey will be responsible for the business, financial, and legal functions of SGX. In particular, he will work with SGX’s board “to create and implement successful strategies to form lead discovery partnerships with biotechnology, pharmaceutical, and agricultural companies.”
Before joining San Diego-based SGX, Grey was president and CEO of Trega Biosciences from 1999 to 2001 until its acquisition by Lion Bioscience. Between 1994 and 1998, the new CBO was president of BioChem Therapeutics, a subsidiary of BioChem Pharma.
Hybridon on Tuesday announced that it had appointed Ronald N. Germain as a senior scientific advisor.
He will help Hybridon develop its CpG-based immunomodulatory oligonucleotides, as well as the Cambridge, Mass.-based company’s antisense compounds for gene targets, which Hybridon may develop alone or in partnerships.
Germain is also a scientific advisor to MedImmune, Cell Genesys, Mojave Therapeutics, and Alexion Pharmaceuticals, and is a consultant with the Genetics Institute, Hybridon said.
GeneProt , of North Brunswick, NJ, has hired Ranald Sutherland as vice president of business development, the company said on Tuesday.
Sutherland, who will report directly to CEO Cedric Loiret-Bernal, will be responsible for developing new partnerships with pharmaceutical companies worldwide, overseeing product out-licensing and in-licensing, and expanding strategic alliances with technology companies, GeneProt said in a statement.
Before joining GeneProt’s executive tier, Sutherland was vice president of business development at F. Hoffmann-La Roche, the German pharmaceutical giant.
Harvard Bioscience has brought in Susan Zusman to be vice president of research and development for its Union Biometrica subsidiary, the company announced on Monday.
“The addition of Susan to the current team of Union Biometrica scientists … gives us one of the premier scientific and managerial teams in using model organisms for drug discovery research,” according to a Harvard Bioscience statement. “Their expertise … [will] help our customers … overcome bottlenecks in the target validation, high-throughput/high content screening, and ADMET screening aspects of drug discovery.”
Zusman came to Harvard Bioscience after serving as executive director of functional genomics for Novartis Pharmaceuticals.
Promoted? Changing jobs? GenomeWeb wants to know. Help us keep track of you by e-mailing us at [email protected] PEOPLE , a roundup of personnel comings and goings in genomics, appears each Wednesday.